Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
GFP is a common fusion protein tag that enables protein expression to be monitored, quantified, and localized within the complex environment of the cell
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Subscribe To Our Newsletter & Stay Updated
